Firms
Parkinson's Research Ventures
London, United Kingdom
Parkinson’s Research Ventures Limited is the separate wholly owned drug-development investment subsidiary of Parkinson’s UK, exact active UK company11228595 incorporatedFebruary27,2018. The public Parkinson’s Research Ventures programme was formerly Parkinson’s Virtual Biotech and is led by Parkinson’s UK in partnership with the separately incorporated Parkinson’s Foundation. It supports pre-seed, seed and SeriesA neuroscience development projects and clinical studies aimed at disease modification and unmet Parkinson’s symptoms. Funding arrangements include grants, company investments and convertible research loans; a published scientific portfolio is not necessarily a list of equity holdings. The official programme uses Parkinson’s UK’s authentic shared parent brand/logo; an independent unit logo was not verified. May2026 literature says overGBP33M committed across the programme, not a closed LP fund or verified amount paid to companies. Annual2025 accounts explicitly identify convertible-loan debtors funding EndLyzTherapeuticsInc through this subsidiary; group EndLyz equity and subsidiary loan arrangements must remain distinct. The charity’s24.203M intercompany loan receivable is parent-to-subsidiary financing, not EndLyz financing; EndLyz’s720K reported fairvalue is not a new paid ticket. The subsidiary has ten current statutory officers, seven named operating research/investment staff and seven external drug-discovery advisers; advisory/operating roles do not imply statutory directorship. IanGarland is chair fromFebruary2026 with exact chairday undisclosed; CompaniesHouse separately confirms his statutory director appointmentMay30,2023. MatthewDurdy resigned statutorydirectorshipMarch25,2026 and is separately marked former. Experimental research outcomes are not independent clinical efficacy or marketing approval claims.
- Founded
- 2018
- Type
- Venture capital
Funds0
No funds on record yet.
Team
Operations and support
 Alan NaylorExternal Drug Discovery Adviser |
 Ana MoraClinical Studies Portfolio Manager |
 Ann HayesExternal Drug Discovery Adviser |
 Burrinder GrewalDirector |
 Chris SwainExternal Drug Discovery Adviser |
 Damian CrowtherExternal Drug Discovery Adviser |
 David DexterDirector · Professor David Dexter, Director of Research |
 David ShawDrug Discovery Manager (Chemistry) |
 Fiona DucotterdDirector |
 Ian GarlandDirector and Chair (chair from February 2026, exact chair day unknown) |
 Iwona ZiomkiewiczDrug Discovery Manager (Biology) |
 Jina Elise SwartzDirector |
 John DavisExternal Drug Discovery Adviser |
Jonathan BehrDirector |
 Judeth NevilleCompany Secretary |
Lilian AlcarazDirector |
 Lynsey BilslandDirector · Managing Director of Parkinson's Research Ventures |
 Manfred AuerExternal Drug Discovery Adviser |
 Michael HurleySenior Drug Discovery Manager (Biology) |
 Michael RowleyExternal Drug Discovery Adviser |
 Oliver JarvisBiotech Investment Manager |
 Sonia GandhiDirector |
Co-investing
No co-investors on record yet.
Investments
| $—Unknown date |  NRG Therapeutics | Parkinson's Research Ventures |
| $—Unknown date | NRG Therapeutics | Parkinson's Research Ventures |
| $—Unknown date |  EndLyz Therapeutics | Parkinson's Research Ventures |